Difference and clinical significance of serum GP73 between alcoholic liver disease and non-alcohol fatty liver disease
10.3760/cma.j.issn.1003-9279.2017.02.017
- VernacularTitle: 酒精性肝病与非酒精性脂肪肝患者血清GP73水平差异及意义
- Author:
Aiguo ZHOU
1
;
Jun HOU
2
;
Xin FENG
3
;
Yubo HUANG
3
;
Boan LI
2
Author Information
1. The Zaozhuang Shizhong People's Hospital, Zaozhuang, 277100, China
2. The No 302 Hospital of the People′s Liberation Army, Beijing, 100039, China
3. Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China
- Publication Type:Journal Article
- Keywords:
Alcoholic liver disease;
Non-alcohol fatty liver disease;
Golgi protein 73;
Differentiating diagnosis
- From:
Chinese Journal of Experimental and Clinical Virology
2017;31(2):162-164
- CountryChina
- Language:Chinese
-
Abstract:
Objective:The present study was designed to evaluate the clinical significance of serum GP73 in patients with alcohol liver disease.
Methods:Thirty-two patients with alcoholic liver disease (ALD), 40 patients with non-alcohol fatty liver disease(NFLAD), and 40 apparently healthy individuals were included in this study.
Results:Compared with Those of healthy control population(43.91±19.02 ng/ml), the serum GP73 levels in ALD patients(93.39±66.91 ng/ml) were significantly increased, and also markedly higher than those of NFLAD patients (55.38±21.00 ng/ml). Taken the NFALD as"healthy controls" population, and ALD population as"patients" , the GP73 may be used to differentiate the ALD from NFLAD. The area of ROC analysis was 0.66(95%CI: 0.52~0.80, P=0.02). We set 75.65 ng/ml as the cut-off value for ALD diagnosis, the sensitivity and specificity were 50.0% and 85.0% respectively.
Conclusion:Serum GP73 levels in ALD patients were significantly higher than those of NFALD patients. GP73 may be a new marker for differentiating ALD from NFALD.
